J Pediatr by Khowaja, Asif Raza et al.
Effectiveness of Haemophilus influenzae Type b Conjugate 
Vaccine on Radiologically-Confirmed Pneumonia in Young 
Children in Pakistan
Asif Raza Khowaja, MSc1, Syed Mohiuddin, MRCGP1, Adam L. Cohen, MD, MPH2, Waseem 
Mirza, FCPS3, Naila Nadeem, FCPS3, Talha Zuberi, FCPS3, Basit Salam, FCPS3, Fatima 
Mubarak, FCPS3, Bano Rizvi, MSc1, Yousuf Husen, FCPS3, Khatidja Pardhan, FRCR, 
FCPS1, Khalid Mehmood A. Khan, FCPS, MCPS, DCH4, Syed Jamal Raza, FCPS, MRCP, 
MCPS4, Hassan Khalid Zuberi, MBBS, DCH5, Sultan Mustafa, MCPS, FCPS6, Salma H. 
Sheikh, MRCP7, Akbar Nizamani, FCPS7, Heermani Lohana, FCPS1, Kim Mulholland, 
MBBS, FRACP, MD8, Elizabeth Zell, MStat2, Rana Hajjeh, MD2, Altaf Bosan, DABP9, and 
Anita K. M. Zaidi, MBBS, SM, FAAP1 on behalf of the Pakistan Hib Vaccine Study Group*
1Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan
2Division of Bacterial Diseases, National Center of Immunization and Respiratory Diseases, 
Centers for Disease Control and Prevention, Atlanta, GA
3Department of Radiology, Aga Khan University
4National Institute of Child Health, Hospital
5Sindh Government Children Hospital, Nazimabad
6Abbasi Shaheed Hospital, Karachi, Pakistan
7Liaqual University Medical Health Sciences Hospital, Hyderabad, Pakistan
8Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical 
Medicine, United Kingdom
9Federal Expanded Program on Immunization, Ministry of Health, Islamabad, Pakistan
Abstract
Objective—The effectiveness of Haemophilus influenzae type b (Hib) vaccine in preventing 
severe pneumonia in Asian children has been questioned, and many large Asian countries yet to 
introduce Hib conjugate vaccine in immunization programs. The primary objective of this study 
was to assess Hib conjugate vaccine effectiveness (VE) on radiologically-confirmed pneumonia in 
children born after introduction of Hib conjugate vaccine in Pakistan.
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Study design—A matched case-control study enrolled cases of radiologically-confirmed 
pneumonia in several hospitals serving low-income populations during 2009–2011. Cases were 
matched by age and season with 3 hospital and 5 neighborhood controls. Pneumonia was 
diagnosed using standardized World Health Organization criteria for chest radiograph 
interpretation. Matched OR were estimated for VE.
Results—A total of 1027 children with radiologically-confirmed pneumonia were enrolled; 975 
cases, 2925 hospital controls, and 4875 neighborhood controls were analyzed. The coverage for 3 
doses of diphtheria-tetanus-pertussis-hepatitis B-Hib conjugate vaccine was 13.7%, 18%, and 
22.7% in cases, hospital controls and neighborhood controls, respectively. Estimated Hib VE for 
radiologically-confirmed pneumonia was 62% with 3 doses of vaccine using hospital controls and 
70% using neighborhood controls.
Conclusions—Hib conjugate vaccine prevented a significant fraction of radiologically-
confirmed pneumonia in children in Pakistan. Maximizing impact on child survival needs 
improved immunization coverage.
Childhood pneumonia remains the leading cause of child mortality in developing countries, 
including Pakistan.1–3 It is estimated that of all cases of pneumonia, 7%–13% are severe, 
requiring hospitalization and may lead to death in the absence of appropriate 
management.4,5 Two major etiologic agents of severe pneumonia in children are 
Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae, both effectively 
preventable through vaccines.6,7 However, determining bacterial pneumonia etiology by 
traditional microbiology has been challenging because of insensitive methods, resulting in a 
serious underestimation of disease burden, particularly in Asia where high antimicrobial use 
prior to tertiary care health facility presentation is frequently noted, rendering cultures 
sterile.8 The combination of insensitive surveillance methods for invasive Hib disease and 
the equivocal findings from a large cluster-randomized Hib conjugate vaccine-probe study in 
Indonesia9 has resulted in large Asian countries including China and India delaying the 
introduction of Hib conjugate vaccine in routine childhood immunization programs.8
Carefully conducted acute bacterial meningitis surveillance studies using nonculture 
methods for etiologic diagnosis documented a substantial burden of invasive Hib and 
pneumococcal disease in Pakistan,10–12 and it is likely that Hib, therefore, also causes a 
substantial burden of pneumonia in Pakistan.6 In 2000, Pakistan was estimated to have 410 
478 cases of Hib pneumonia in children aged <5 years.7 The availability of financing by the 
GAVI Alliance led to a decision by the Government of Pakistan to introduce the pentavalent 
(diphtheria-tetanus-pertussis-hepatitis B-Hib [DTP-Hep B-Hib]) vaccine in the country’s 
Expanded Program on Immunization (EPI) in 2009. Pentavalent vaccine in routine EPI is 
scheduled for children at the age of 6, 10, and 14 weeks, respectively. The primary objective 
of this study was to assess the impact of introduction of Hib conjugate vaccine in Pakistan 
by measuring vaccine effectiveness (VE) against prevention of radiologically-confirmed 
pneumonia in children born after the introduction of Pentavalent vaccine in the country’s 
EPI. We also aimed to identify risk factors for radiologically-confirmed pneumonia in 
children in Pakistan.
Khowaja et al. Page 2
J Pediatr. Author manuscript; available in PMC 2018 January 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Methods
A matched case-control study began immediately following the introduction of pentavalent 
vaccine in the Pakistan national EPI in January 2009. Sentinel surveillance was established 
at several public and private secondary and tertiary level health facilities serving low-income 
populations in 3 districts (Matiari-Sindh, Hyderabad-Sindh, and Jhelum-Punjab) and in the 
mega-city of Karachi, in Sindh in southern Pakistan. A total of 22 health facilities (9 public 
and 13 private) were included in this study based on: (1) parental/caregivers’ health seeking 
preferences/utilization assessed on baseline cross-sectional survey in the study areas; (2) 
more than 20 pediatric admissions weekly at the hospital; (3) availability of chest 
radiography (either digital or manual with at least a 100 mA machine); and (4) willingness 
of hospital administration to participate in the proposed evaluation. Screening for eligible 
cases was conducted in outpatient and inpatient areas at each sentinel site for children aged 
<5 years by a research officer. Children presenting with signs of acute respiratory infection 
were classified as suspected pneumonia if they presented with fast respiratory rate (>50/
minutes) and fever (>101°F).13,14 Among these, parents/guardians of children who had chest 
indrawing as a sign of severe pneumonia,14 who were age-eligible to have received at least 1 
dose of pentavalent vaccine, and were resident in the predefined catchment population were 
invited to participate in the study by a study physician. Children were excluded if they were 
previously enrolled as a case, if there was parental refusal, or if they lived outside the 
catchment area from which neighborhood controls could be enrolled. Death of the child did 
not exclude a case. A case report form recording baseline characteristics was completed if 
the parent/guardian provided informed consent. Chest radiographs of study-eligible children 
were obtained within 24 hours of hospital admission, and interpreted at first by the onsite 
study physician. Digitized images of chest radiographs were made using a VIDAR scanner15 
(VI-DAR Systems Corporation, 365 Herndon Parkway Herndon, VA 20170) for all 
radiographs read as pneumonia, and every tenth radiograph (sequentially) read by the study 
physician as “no pneumonia.” The digitized images were separately sent to 2 pediatric 
radiologists who were trained in the interpretation of chest radiographs with a diagnosis of 
radiologically-confirmed pneumonia according to World Health Organization case definition 
of presence of substantial alveolar consolidation16,17 for second level interpretation at Aga 
Khan University Hospital (AKUH), in Karachi, Pakistan, on the same day. These 2 
radiologists were not given any clinical information about the child and were blinded to each 
other’s interpretations. A senior pediatric radiologist (also trained in World Health 
Organization standardized interpretation of chest radiographs)16 served as arbiter for 
discordant chest radiograph interpretations. A case of radiologically-confirmed pneumonia 
was diagnosed based on the agreement of the 2 blinded radiologists at AKUH, or diagnosis 
by the senior radiologist if the AKUH radiologists were discordant.
Selection of Hospitals and Neighborhood Controls
For each case of radiologically-confirmed pneumonia, 3 age-matched hospital controls were 
enrolled from the same hospital, and 5 neighborhood controls were enrolled from the 
community in which the case child lived. Controls were eligible if the child was age 
matched (±4 weeks for case children <12 months; and ±8 weeks of age for case children ≥12 
months), age eligible (at least 6 weeks) to receive the first dose of pentavalent vaccine, and a 
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resident of study catchment areas. Children (controls) were excluded if child had been 
previously enrolled as a case of severe pneumonia or meningitis in the previous 8 weeks, 
was a sibling of a previously recruited case/control who lived in the same household, or had 
a current severe illness possibly due to Hib. For identification of hospital controls, the study 
staff generated a list of all eligible children at the hospital from patient triage records (−7 to 
30 days) based on the date of admission of case child, and 3 hospital controls were randomly 
selected and recruited after obtaining written parental consent. For identification of 
neighborhood controls, the project research assistants and community health workers visited 
the geographic area of the case child. A random direction was established by means of 
rotating a bottle, and the first household was approached to determine child’s eligibility. 
Upon identification of the first household with an age eligible child, study staff invited the 
parents to participate in the study and obtained written parental consent. Subsequently, staff 
approached households using a systematic sampling technique with a skip pattern of 3 
households after each eligible household, and continued in this fashion until 5 matched 
neighborhood controls were enrolled. The recruitment of hospital or neighborhood controls 
was made within 30 days from the hospital admission date of the case to account for 
seasonality of exposure.
Sample Size
The sample size was calculated using the NCSS PASS v. 11 software18 (Dr. Jerry L. Hintze 
and NCSS, East Kaysville, Utah) for matched case-control study design. This study was 
designed to detect a VE of 20% for radiologically-confirmed pneumonia with 2 or more 
doses of Hib conjugate vaccine.19,20 Using alpha error of 0.05, power of 80%, 50% 
pentavalent vaccine coverage, and correlation coefficient for vaccination between matched 
cases and controls of 0.20, we estimated needing 960 cases with 3 hospital controls and 839 
cases with 5 neighborhood controls. The target enrollment was 960 cases.
Ascertainment of Vaccination Exposure, Sociodemographic Information, and 
Anthropometric Assessment
Parents or primary caregivers of children (both cases and controls) were interviewed about 
the child’s past and current illnesses, family’s sociodemographic information, and child’s 
vaccination history. Each child’s height and weight measurement were also recorded. The 
vaccination history was verified with the child’s vaccination card when available. In 
addition, a computerized vaccination registry was maintained for all children in the selected 
rural districts through monthly visits to all local EPI facilities (Matiari and Jhelum), from 
where vaccination status for recruited cases and controls could be documented when the 
vaccination card was not available. In the urban areas (Hyderabad and Karachi) where the 
immunization registry was not available, in the event of a caretaker reporting receipt of 
vaccine that could not be verified by card, project staff visited the nearest vaccination facility 
from where parents reported to have their child vaccinated to obtain the relevant record. 
Only verbal reports were used from parents/guardians who reported that their child was 
never vaccinated.
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Vaccine Coverage Surveys (Baseline and End-line)
Cross-sectional vaccine coverage surveys for routine immunizations were conducted first at 
baseline (April–June 2008) and second at end of case-control study enrollment (October–
December 2011) at the selected study sites in Pakistan. The estimated sample size was 3850 
households for the baseline survey and 3508 households for the end-line survey, assuming 
50% vaccine coverage, level of significance 95%, and level of absolute precision 3%.
We used the multiple indicator cluster survey technique,21 and households with age eligible 
children (12–23 months) were randomly selected from each Union Council (subdistrict 
administrative unit for population of 25 000–30 000 thousands) based on the population 
proportional to size. Parents of age eligible children were invited to participate in the survey, 
and written consent was obtained. Child’s vaccination status (verbal history) was ascertained 
and verified with vaccination card (when available).
Data Quality and Statistical Analyses
The senior project staff at each site made random observations of parental interviews and 
conducted 10% of parental re-interviews at hospital and in community settings for ensuring 
data quality control. The case control registry forms were independently double-entered in 
real time by trained data input operators using software developed in Visual FoxPro v 6.0 
(Microsoft Corporation, United States of America ) Data were analyzed in SAS 9.1.3 
software (SAS Institute, Cary, North Carolina). Median age and proportion receiving 
pentavalent vaccine doses were calculated, and conditional multivariate logistic regression 
was applied to identify significant risk factors for radiologically-confirmed pneumonia. Hib 
VE, defined as (1 − aOR) × 100%, and the associated 95% CI were estimated for each dose 
compared with 0 dose; we also compared ≥1 dose and ≥2 doses with 0 dose. VE estimates 
were adjusted for confounders and risk factors (P value <.05). This study received ethical 
approval from Ethics Review Committee of Aga Khan University, Karachi, Pakistan.
Results
Over 3 years of surveillance (January 2009–October 2011), a total of 6013 eligible cases 
were identified (Figure). Ninety eight percent (5892) of eligible children underwent chest 
radiography, and of these radiographs, 1027 (17.4%) were interpreted as radiologically-
confirmed pneumonia (Figure). Among these, 52 cases were excluded in the analysis phase 
because matched controls could not be identified in the stipulated time period, or 
inappropriate controls were selected.
A total of 975 cases and their associated controls were analyzed. Median age of cases was 5 
months (minimum 1.5; maximum 31 months); 810 (83%) were <12 months of age. Of all 
cases, 678 (69.5%) were recruited from Karachi, 158 (16.2%) from Hyderabad, 104 (10.6%) 
from Matiari (Sindh), and 35 (3.6%) from Jhelum district in Punjab. A total of 2925 hospital 
controls and 4875 neighborhood controls were analyzed. Among neighborhood control 
children who had received 3 doses of pentavalent vaccine, the median age at time of 
pentavalent 3 vaccination was 17 weeks (minimum 10- maximum 69). The most common 
diagnosis for hospital controls was acute gastroenteritis (Table I).
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On multivariate analysis, a number of risk factors were found to be significantly associated 
with radiologically-confirmed pneumonia. Lack of paternal education, use of biomass/
charcoal/wood for heating, at least 1 other child aged <5 years (other than the case/control 
child) in the same household, wasting, and underweight were significant risk factors for 
radiologically-confirmed pneumonia compared with hospital and neighborhood controls 
(Table II).
The coverage for 3 doses of pentavalent vaccine (DTP-Hep B-Hib) was 13.7%, 18%, and 
22.7% in children enrolled as cases, hospital controls, and neighborhood controls, 
respectively. Hib conjugate VE for radiologically-confirmed pneumonia was 62% (95% CI 
47%–73%), with 3 doses of pentavalent vaccine using hospital controls, and 70% (95% CI 
59%–78%) using neighborhood controls (Table III). The results of the baseline and end-line 
vaccine coverage survey are presented in Table IV.
Discussion
Our study provides evidence that a significant fraction of radiologically-confirmed 
pneumonia can be prevented by Hib conjugate vaccine in Pakistani children. The point 
estimate for effectiveness of 3 doses of Hib conjugate vaccine ranged from 62%–70%, 
depending on the type of control used. These results are not that dissimilar from what has 
been seen in other Hib VE studies.22 Compared with other Asian countries where Hib VE 
studies against radiologically-confirmed pneumonia have been done, our findings confirm 
earlier observations from Bangladesh based on a smaller case-control study and are contrary 
to the lack of Hib conjugate vaccine efficacy reported from Indonesia.9,19 Interpretation of 
Hib conjugate vaccine trial results in Indonesia may have been affected by the development 
of strong herd immunity in the neighboring populations, if there was unrecognized 
population mingling, thus, underestimating vaccine efficacy, as has been shown in cholera 
vaccine trials.23
Several reasons may underlie the finding of much higher than expected point estimates of 
VE in our study compared with The Gambian trial findings where Hib VE was found to be 
21% (95% CI 5%–35%). One major characteristic for which our cases were different from 
the control population selected is that cases were significantly more malnourished than 
controls (Table II). Malnutrition increases the risk of developing severe, radiologically-
confirmed pneumonia, the end-point used in this study. If the unvaccinated population is 
more likely to be exposed to the disease than the vaccinated, this can result in an 
overestimation of the true VE.24 It is also possible that in children with severe malnutrition, 
Hib is responsible for a larger fraction of severe, radiologically proven pneumonia that can 
be prevented by vaccine than in well-nourished children, especially in the very young child. 
It is worth noting that the median age of cases enrolled in this study was only 5 months, 
much lower than other published studies.
It is also possible that some biases existed in control selection and their vaccine exposure 
ascertainment. For example, results might have been biased if, despite thorough training in 
enrolling all eligible controls, some research staff selectively dropped controls with no 
vaccination card and replaced them with other controls who had vaccination cards. This 
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could have resulted in overestimating vaccine coverage in neighborhood controls, in turn 
resulting in an overestimated VE. There may also have been unidentified and unmeasured 
potential confounders that we were unable to control for. Despite these potential biases, 
there is internal validity for the VE estimates because the VE rises with increasing doses of 
Hib conjugate vaccine (Table III).
This study, as has been reported elsewhere, highlights the effect of lack of paternal 
education, use of biomass/charcoal/wood for heating, number of children <5 years of age in 
the household, and malnutrition as significant risk factors for severe pneumonia.25,26 More 
crowding was identified in the neighborhood controls, and it was most likely due to 
inaccurate reporting by case families. Cases were interviewed in hospital compared with 
direct observation in control neighborhood homes.
The strengths of our study are the large sample size, rigorously standardized radiograph 
interpretation throughout the study using 3 blinded radiologists, and the extensive efforts 
made for accurate vaccine exposure ascertainment. For enhancing card retention among 
rural populations, where our baseline vaccine coverage survey had shown poor retention, we 
distributed plastic pouches to all vaccinators at local EPI facilities to be distributed to 
families for card retention. This had a marked effect on increasing vaccine card retention by 
23%–30% as observed on end-line vaccine coverage survey in districts Matiari and Jhelum 
(Table IV). In addition, a prospective registry of all children coming to each local EPI 
facility in the rural areas was also maintained by entering the data of each child into an 
electronic database through monthly visits to the centers. In this way, for over 95% of the 
recruited cases and controls from rural areas, vaccination history could be cross-verified 
with our computerized registry. Accurate exposure ascertainment remained a challenge in 
urban areas among those reporting no vaccine receipt, where parental report of no 
vaccination ever had to be taken as evidence of receipt of no vaccine (Table I).
Operational challenges included frequent lack of electricity in rural areas delaying 
radiographs and digitization and the difficult security situation in some areas of Karachi 
where cases came from and controls had to be recruited, sometimes resulting in delays in 
control enrollment.
Only 23% of community controls and 18% of hospital controls had received 3 doses of 
pentavalent vaccine. The findings of low and delayed vaccination uptake among the study 
population underscore the fact that vaccines in high child mortality countries such as 
Pakistan do not reach those most in need.27–29 Before pentavalent vaccine was introduced in 
national EPI in Pakistan, the coverage for 3 doses of tetravalent vaccine (DTP-Hep B) on our 
baseline population-representative survey in the year 2008 was 69% (Table IV). Comparing 
with baseline, the overall coverage for 3 doses of pentavalent vaccine (DTP-Hep B-Hib) on 
the end-line survey in the year 2011 had considerably improved to 86% (Karachi was not 
surveyed again as these data were available from other work). These estimates reflect 
vaccine coverage in general in the community of the study sites. However, our study 
population of cases and controls were overwhelmingly poor, lacking the most basic of 
amenities, and had lower vaccination rates (39%, 44%, and 53% in cases, hospital controls, 
and neighborhood controls aged 12–23 months, respectively). They had high rates of 
Khowaja et al. Page 7
J Pediatr. Author manuscript; available in PMC 2018 January 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
malnutrition even among community controls (15% with moderate to severe wasting, 23% 
underweight, and 35% stunted). To maximize the child survival benefit of these Global 
Alliance for Vaccines and Immunization-supported vaccines, it is imperative to remove 
inequities in vaccine access. Preventing childhood pneumonia is important for reaching 
Millennium Development Goal 4 to reduce child mortality, and this study supports the 
importance of Hib conjugate vaccine to reach those goals.
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Figure. 
Levels of chest radiograph interpretation for radiologically-confirmed pneumonia. Suspected 
pneumonia = Fast respiratory rate (>50/min) and fever (>101°F). Study eligible = Lower 
chest indrawing, age eligible to receive first dose of pentavalent vaccine; and resident of 
study catchments. Definite radiologically-confirmed pneumonia = Alveolar consolidation 
observed in any of the lungs parenchyma. *Includes 291 cases where study physician read 
film negative. †52 cases dropped because appropriate controls could not be found in 
stipulated time period or controls were inappropriately selected.
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